Symbiotec Pharmalab Ltd (SYMBIOTEC) — Insider Trading | 3 September 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company issued Fair Disclosure Code under SEBI PIT Regulations
🔄 What Changed
Policy effective December 15, 2025, for UPSI dissemination
🔮 What's Next
Policy automatically updates with SEBI regulation changes
💡 Investor Takeaway
Investors should monitor disclosures through official channels for material updates

Symbiotec Pharmalab disclosed its Fair Disclosure Code effective December 15, 2025, to ensure timely public sharing of unpublished price sensitive information and prevent insider trading violations under SEBI regulations.

📄 View Original Announcement (PDF)

About Symbiotec Pharmalab Ltd (SYMBIOTEC)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹6,197.7 Cr

View full SYMBIOTEC stock details →

📡 Get AI alerts when SYMBIOTEC files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SYMBIOTEC — Free

📊 More SYMBIOTEC filings

See all SYMBIOTEC filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SYMBIOTEC files new disclosures

Track SYMBIOTEC filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SYMBIOTEC — Free

Free account · 2 AI queries/day